• 1
    Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 917.
  • 2
    Lenhoff S, Hjorth M, Holmberg E, Turesson I, Weston J, Nielsen JL, Wisloff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen H, Lamvik J, Lofvenberg E, Nesthus I, Rodjer S. Impact on survival of high dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic myeloma Study Group. Blood 2000; 95: 711.
  • 3
    Cornwell GG III, Pajak TF, McIntyre OR, Kochwa S, Dosik H. Influence of renal failure on myelosuppressive effects of melphalan: cancer and leukemia group B experience. Cancer Treat Rep 1982; 66: 47581.
  • 4
    Moreau P, Kergueris M-F, Milpied N, Le Tortorec SL, Mahe B, Bulabois C-E, Rapp M-J, Larousse C, Bataille R, Harousseau J-L. A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. Br J Haematol 1996; 95: 52730.
  • 5
    Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. The systemic administration of intravenous melphalan. J Clin Oncol 1988; 6: 176882.
  • 6
    Gertz MA, Lacy MQ, Dispenzieri A, Ansell A, Elliot SM, Gastineau DA, Inwards DJ, Micallef INM, Porrata LF, Tefferi A, Litzow MR. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34: 102531.
  • 7
    Reece PA, Hill HS, Green RM, Morris RG, Dale BM, Kotasek D, Sage RE. Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol 1988; 22: 34852.
  • 8
    Gera S, Musch E, Osterheld HK, Loos U. Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma. Cancer Chemother Pharmacol 1989; 23: 7680.
  • 9
    Chang SY, Alberts DS, Farquhar D, Melnick LR, Walson PD, Salmon SE. Hydrolysis and protein binding of melphalan. J Pharm Sci 1978; 67: 6824.
  • 10
    Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N, Tricot G. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 8229.
  • 11
    Kühne A, Sezer O, Heider U, Meineke I, Muhlke S, Niere W, Overbeck T, Hohloch K, Trümper L, Brockmöller J, Kaiser R. Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clin Pharmacol Ther 2008; 83: 74957.
  • 12
    Junge W, Wilke B, Halabi A, Klein G. Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe method. Clin Chim Acta 2004; 344: 13748.
  • 13
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 14
    Jones GRD, Imam SK. Validation of the revised MDRD formula and the original Cockroft and Gault formula for estimation of the glomerular filtration rate using Australian data. Pathology 2009; 41: 37982.
  • 15
    Keys A, Fidanza F, Karvonen M, Kimura N, Taylor H. Indices of relative weight and obesity. J Chronic Dis 1972; 25: 32943.
  • 16
    Mosteller RD. Simplified calculation of body surface area. N Engl J Med 1987; 317: 1098.
  • 17
    Janmahasatian S, Duffull S, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean body weight. Clin Pharmacokinet 2005; 44: 105165.
  • 18
    Nath CE, Zeng L, Eslick A, Trotman J, Earl J. An isocratic UV HPLC assay for analysis of total and free melphalan concentrations in human plasma. Acta Chromatogr 2008; 20: 38398.
  • 19
    Nath CE, Shaw PJ, Montgomery K, Earl JW. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol 2007; 64: 15164.
  • 20
    Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 32932.
  • 21
    Gastonguay MR, El-Tahtawy A. Effect of NONMEM minimization status and number of replicates on bootstrap parameter distributions for population pharmacokinetic models: a case study. Clin Pharmacol Ther 2005; 77: 2, doi:10.1016/j.clpt.2004.11.010.
  • 22
    National Cancer Institute, USA. Common terminology Criteria for Adverse Events v 3.0 (CTCAE). Publish date: 12 December 2003. Available at (last accessed 31 March 2003).
  • 23
    Bladē J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 111523.
  • 24
    Carlson K. Melphalan 200 mg/m2 with blood stem cell support as first line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 2005; 35: 98590.
  • 25
    Bjorntorp P. Obesity. Lancet 1997; 350: 4236.
  • 26
    World Health Organization. Report of a WHO Consultant on Obesity: Preventing and managing the global epidemic. Geneva: WHO, 1998.
  • 27
    Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 11933.
  • 28
    Han PY, Duffull SB, Kirkpatrick CMJ, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82: 5058.
  • 29
    Grieg NH, Sweeney DJ, Rapoport SI. Melphalan concentration dependent plasma protein binding in healthy humans and rats. Eur J Clin Pharmacol 1987; 32: 17985.
  • 30
    Ahmed AE, Hsu TF, El-Azhary RA, Moawad H, Costanzi J. Macromolecular interactions of 14C-ring melphalan in blood. Biochem Pharmacol 1982; 31: 16159.
  • 31
    Vassal G, Tranchand B, Valteau-Couanet D, Mahē C, Couanet D, Schoeppfer C, Grill J, Kalifa C, Hill C, Ardiet C, Hartmann O. Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma. Bone Marrow Transplant 2001; 27: 4717.